Europe - Frankfurt Stock Exchange - FRA:BAYN - DE000BAY0017 - Common Stock
The current stock price of BAYN.DE is 34.378 EUR. In the past month the price increased by 27.64%. In the past year, price increased by 70.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.36 | 209.67B | ||
| 1SAN.MI | SANOFI | 11.36 | 209.67B | ||
| SAN.PA | SANOFI | 11.32 | 209.04B | ||
| MRK.DE | MERCK KGAA | 14.19 | 52.61B | ||
| UCB.BR | UCB SA | 38.15 | 47.64B | ||
| UNC.DE | UCB SA | 37.8 | 47.21B | ||
| 1BAYN.MI | BAYER AG-REG | 6.32 | 33.17B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.12 | 10.35B | ||
| IPN.PA | IPSEN | 12.04 | 10.36B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 102.16 | 9.46B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 18.49 | 7.90B | ||
| VIRP.PA | VIRBAC SA | 20.56 | 2.99B |
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 89,556 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
BAYER AG-REG
Kaiser-Wilhelm-Allee 1
Leverkusen NORDRHEIN-WESTFALEN DE
Employees: 90587
Phone: 49214301
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 89,556 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
The current stock price of BAYN.DE is 34.378 EUR. The price increased by 0.67% in the last trading session.
BAYER AG-REG (BAYN.DE) has a dividend yield of 0.36%. The yearly dividend amount is currently 0.13.
BAYN.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BAYN.DE.
BAYER AG-REG (BAYN.DE) has a market capitalization of 33.77B EUR. This makes BAYN.DE a Large Cap stock.
ChartMill assigns a technical rating of 10 / 10 to BAYN.DE. When comparing the yearly performance of all stocks, BAYN.DE is one of the better performing stocks in the market, outperforming 95.49% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to BAYN.DE. BAYN.DE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months BAYN.DE reported a non-GAAP Earnings per Share(EPS) of 5.34. The EPS decreased by -8.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.19% | ||
| ROE | -0.67% | ||
| Debt/Equity | 1.11 |
28 analysts have analysed BAYN.DE and the average price target is 29.58 EUR. This implies a price decrease of -13.97% is expected in the next year compared to the current price of 34.378.
For the next year, analysts expect an EPS growth of -6.5% and a revenue growth -1.37% for BAYN.DE